Publication of Audited Financials of the Company for the Quarter and Year ended 31.03.2025 in News papers
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Ltd has submitted newspaper clippings of its audited financial results for the fourth quarter and full year ended 31 March 2025 to BSE, as required by SEBI rules. The results were published in Business Standard (English) and Andhraprabha (Telugu) on 31 May 2025, and were approved by the Board of Directors on 29 May 2025. For the full year FY25, total revenue from operations fell to Rs. 11,432.73 lakhs from Rs. 15,732.94 lakhs in FY24, a drop of around 27%. Net profit after tax also declined to Rs. 438.00 lakhs (FY24: Rs. 554.90 lakhs), with EPS coming in at Rs. 5.82 versus Rs. 7.82 the previous year. The Q4 standalone numbers were particularly weak, with net profit at Rs. 89.31 lakhs versus Rs. 266.19 lakhs in the same quarter last year.
Shareholders should note the sharp year-on-year decline in both revenue and profits, especially the 66% drop in Q4 net profit, which could weigh on short-term investor sentiment. That said, the audited numbers are not new — they were already filed with the stock exchange earlier — and this filing is just a routine newspaper publication to meet disclosure rules.